---
schema_version: "secwatch.filing_event.v1"
accession: "0001448431-26-000002"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:30:16.260611+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx Q4 net income $5.0M, record adj EBITDA $12.0M; guides FY2026 rev $109-114M

## Summary
- Q4 revenue $32.2M (flat YoY); FY2025 revenue $109.4M (+19% YoY).
- Q4 GAAP net income $5.0M ($0.26/diluted share) vs net loss $0.1M in Q4 2024.
- Q4 adjusted EBITDA record $12.0M; FY2025 adj EBITDA $24.3M.
- FY2026 guidance: revenue $109-114M, adjusted EBITDA $21-25M.
- Board authorizes $10M share repurchase program effective Mar 12, 2026 through Mar 15, 2027.

## SEC filing metadata
- accession: 0001448431-26-000002
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000144843126000002/0001448431-26-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000144843126000002/oprx-20260305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001448431-26-000002
- JSON: https://secwatch.observer/filing/0001448431-26-000002.json
- Plain text: https://secwatch.observer/filing/0001448431-26-000002.txt

## Key facts
- Material Agreements
  OptimizeRx Corp amended Amendment No. 4 (effective 2026-03-02).
  - Action: amendment
  - Agreement: credit facility
  - Effective: 2026-03-02
  source text: On March 2, 2026, OptimizeRx Corporation (the “Company”) entered into Amendment No. 4 to the Financing Agreement (the “Amendment No. 4”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1448431/000144843126000002/0001448431-26-000002-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.